The interleukin-2 receptor alpha chain (also called Tac antigen, P55, and mainly CD25) is a protein involved in the assembly of the high-affinity interleukin-2 receptor, consisting of alpha (IL2RA), beta and the common gamma chain .

2023年4月1日 · CD25 is the alpha-chain of the heterotrimer IL-2 receptor. CD25 is expressed on the surface of both immune and non-immune cells with different frequencies. For cancers, CD25 is expressed at high levels in many types of hematological …

Elevated levels of soluble interleukin-2 receptor α-chain (IL-2Ra/CD25) are detected in the serum of patients with a broad spectrum of conditions associated with T- or B-cell immune activation, including infections, inflammation, lymphomas, and autoimmune disease. 1 For some of these conditions, measurement of IL-2Ra/CD25 levels is used in ...

IL-2 binds to the IL-2 receptor, which has three forms, generated by different combinations of three different proteins, often referred to as "chains": α (alpha) (also called IL-2Rα, CD25, or Tac antigen), β (beta) (also called IL-2Rβ, or CD122), and γ (gamma) (also called IL-2Rγ, γ c, common gamma chain, or CD132); these subunits are ...

CD25 (also known as IL-2Rα receptor or the α-subunit of the IL-2 receptor) is involved in the regulation of T cell function. More specifically, it is encoded by the CD25 region on chromosome 10p15.1, is highly expressed in Tregs, and mediates IL-2 signaling which is indispensable for CD25+CD4+ Treg survival and growth [41].

2020年11月9日 · Here we demonstrate potent single-agent activity of anti-CD25 antibodies optimized to deplete Treg cells, while preserving IL-2-STAT5 signaling on effector T cells and show synergy with...

CD25 deficiency or interleukin 2 receptor alpha deficiency is an immunodeficiency disorder associated with mutations in the interleukin 2 receptor alpha (CD25) (IL2RA) gene. The mutations cause expression of a defective α chain or complete absence thereof, an essential part of high-affinity interleukin-2 (IL-2) receptors.

CD (cluster of differentiation) 69 and CD25 are considered early and late markers of the activation of lymphocytes, respectively. CD25 is a part of the IL-2 receptor and is present on the surface of immune and non-immune cells, with high amounts on …

CD25 is a novel STAT5-dependent marker of leukemic stem cells (LSCs) in CML. • In chronic phase CML, LSCs are usually CD25 + /CD26 + /IL-1RAP +. • CD25 is a functional regulator of LSC expansion and a potential target in CML. • The clinical value of CD25 as an LSC marker is being investigated.

CD25, expressed and secreted by such DC may capture IL-2 and thereby suppress T-cell proliferation, by this means providing an accessory mechanism of DC-mediated immune suppression. We also discuss the implication of DC-derived CD25 for human disease in both cancer and chronic infection.